Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | Director | June 20, 2024 | June 24, 2024 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Director | June 24, 2026 | June 26, 2026 |
| iTeos Therapeutics, Inc.ITOS · Entity 75965 | Director | June 11, 2024 | June 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncternal Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2034-06-20 | Direct | 2,200 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 2,200 · Balance 2,200 F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date.
Praxis Precision Medicines, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,337 |
Ending reported balance
After 2026-06-24 transaction · row 14
14 source rows · reconciled sequenceRow 1 · 2026-06-24 · Exercise / conversion · Acquired 8,566 · Balance 10,903 Row 2 · 2026-06-24 · Exercise / conversion · Acquired 3,034 · Balance 13,937 Row 3 · 2026-06-24 · Sale · Disposed 10 · Balance 13,927 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. Row 4 · 2026-06-24 · Sale · Disposed 120 · Balance 13,807 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $302.500 to $303.440. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 5 · 2026-06-24 · Sale · Disposed 320 · Balance 13,487 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 6 · 2026-06-24 · Sale · Disposed 683 · Balance 12,804 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F4: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $306.365 to $307.180. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 7 · 2026-06-24 · Sale · Disposed 1,240 · Balance 11,564 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F5: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $307.900 to $308.870. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 8 · 2026-06-24 · Sale · Disposed 999 · Balance 10,565 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F6: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $308.900 to $309.790. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 9 · 2026-06-24 · Sale · Disposed 1,750 · Balance 8,815 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F7: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $310.340 to $311.300. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 10 · 2026-06-24 · Sale · Disposed 2,854 · Balance 5,961 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F8: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $311.340 to $312.320. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 11 · 2026-06-24 · Sale · Disposed 1,004 · Balance 4,957 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F9: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $312.370 to $313.280. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 12 · 2026-06-24 · Sale · Disposed 504 · Balance 4,453 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F10: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $313.400 to $314.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 13 · 2026-06-24 · Sale · Disposed 1,279 · Balance 3,174 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F11: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $314.400 to $315.380. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 14 · 2026-06-24 · Sale · Disposed 837 · Balance 2,337 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F12: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.25 · Expires 2034-06-05 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-06-24 · Exercise / conversion · Disposed 8,566 · Balance 0 F13: This option was fully vested as of June 5, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $147.30 · Expires 2032-05-23 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-06-24 · Exercise / conversion · Disposed 3,034 · Balance 0 F14: This option was fully vested as of May 23, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026.
F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $302.500 to $303.440. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $306.365 to $307.180. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F5: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $307.900 to $308.870. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F6: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $308.900 to $309.790. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F7: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $310.340 to $311.300. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F8: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $311.340 to $312.320. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F9: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $312.370 to $313.280. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F10: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $313.400 to $314.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F11: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $314.400 to $315.380. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F12: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F13: This option was fully vested as of June 5, 2025.
F14: This option was fully vested as of May 23, 2025.
iTeos Therapeutics, Inc.
Report date June 11, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-06-11 | Direct | 24,200 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 24,200 · Balance 24,200 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2033-03-01 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,034 | $0.00 Strike: $147.30 | $0.00 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · derivative · entry 16 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,034 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: This option was fully vested as of May 23, 2025. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,566 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · derivative · entry 15 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,566 shares Expires 2034-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: This option was fully vested as of June 5, 2025. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 837 | $315.71 | $264,245.09 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 14 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,337 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F12 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 1,279 | $314.90 | $402,758.38 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 13 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,174 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F11 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $314.400 to $315.380. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 504 | $313.66 | $158,086.15 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 12 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,453 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F10 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $313.400 to $314.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 1,004 | $312.83 | $314,081.32 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 11 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,957 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F9 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $312.370 to $313.280. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 2,854 | $311.91 | $890,202.56 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 10 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,961 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F8 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $311.340 to $312.320. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 1,750 | $310.89 | $544,055.75 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 9 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,815 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F7 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $310.340 to $311.300. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 999 | $309.38 | $309,073.62 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 8 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,565 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F6 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $308.900 to $309.790. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 1,240 | $308.24 | $382,221.32 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 7 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,564 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F5 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $307.900 to $308.870. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 683 | $306.77 | $209,521.86 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 6 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,804 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F4 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $306.365 to $307.180. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 320 | $305.31 | $97,699.20 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 5 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,487 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 120 | $303.13 | $36,375.24 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 4 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,807 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $302.500 to $303.440. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | SaleCommon Stock | 10 | $301.44 | $3,014.40 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 3 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,927 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionCommon Stock | 3,034 | $147.30 | $446,908.20 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 2 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionCommon Stock | 8,566 | $44.25 | $379,045.50 |
DisclosureSEC source: 0001930479-26-000003 · wk-form4_1782508155.xml · nonDerivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:24 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 648 | $0.00 Strike: $240.66 | $0.00 |
DisclosureSEC source: 0001689548-26-000061 · wk-form4_1781299446.xml · derivative · entry 2 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648 Underlying: Common Stock · 648 shares Expires 2036-06-10 F2 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:24 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 1,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-26-000061 · wk-form4_1781299446.xml · nonDerivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,337 F1 · kind: Ms. DeSimone was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 20:55 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 10,520 | $0.00 Strike: $44.04 | $0.00 |
DisclosureSEC source: 0001689548-25-000078 · wk-form4_1751057695.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,520 Underlying: Common Stock · 10,520 shares Expires 2035-06-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 16:05 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Options · Derivative | 2,200 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0000950170-24-076704 · ownership.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 2,200 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:00 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 24,200 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0000950170-24-073253 · ownership.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,200 Underlying: Common Stock · 24,200 shares Expires 2034-06-11 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:56 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 8,566 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001689548-24-000079 · wk-form4_1717714580.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,566 Underlying: Common Stock · 8,566 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 5, 2024. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $5.21 | Not disclosed |
DisclosureSEC source: 0001415889-24-010425 · form4-04052024_040404.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2033-03-01 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 20:01 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 44,766 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0000950170-24-028264 · ownership.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,766 Underlying: Common Stock · 44,766 shares Expires 2034-03-07 F1 · derivative.exercise_date: This stock option shall vest over 3 years, with 1/3 vesting on March 7, 2025, and thereafter in equal monthly installments over the next 24 months, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 11:41 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | PurchaseCommon Stock | 14,500 | $1.75 | $25,375.00 |
DisclosureSEC source: 0001689548-23-000141 · wk-form4_1696938091.xml · nonDerivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 16:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001209191-23-040277 · doc4.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 11:14 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 28,981 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001689548-23-000111 · wf-form4_168674123401611.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,981 Underlying: Common Stock · 28,981 shares Expires 2033-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 12, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:54 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001209191-23-015865 · doc4.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: 1/36th of the shares underlying the Option vest and become exercisable on each monthly anniversary of the Date of Grant. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 18:02 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-23-002047 · doc4.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-04 F1 · derivative.exercise_date: The shares subject to the option vest in 36 equal monthly installments with the first installment vesting on February 4, 2023, subject to the recipient's continued service. Read SEC document |
| May 23, 2022 Filed May 25, 2022 01:14 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 45,511 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001689548-22-000056 · wf-form4_165344126548499.xml · derivative · entry 1 DeSimone Jill · CIK 0001930479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,511 Underlying: Common Stock · 45,511 shares Expires 2032-05-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on May 23, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.